!SUNDAY,!SEPTEMBER!14! ·...

2014 HFSA Annual Scientific Meeting, 9/14-‐17, Caesars Palace, Las Vegas, NV

SUNDAY, SEPTEMBER 14 10:00 AM – 12:00 PM Milano I Clinical Fundamentals I: Hemodynamics in Heart Failure: What You Need to Know (SCAI Joint Session) Moderators: James C. Fang, Salt Lake City, UT Robb D. Kociol, Boston, MA 10:00 AM Hemodynamic Domains: Pressure, Volume and Time John J. Ryan, Salt Lake City, UT 10:15 AM Optimizing Hemodynamic Data Acquisition Paul Sorajja, Minneapolis, MN 10:30 AM Defining Cardiac Output and 'Loading' Conditions Mark H. Drazner, Dallas, TX 10:45 AM Physiologic and Pharmacologic Hemodynamic Assessments James C. Fang, Salt Lake City, UT 11:00 AM Hemodynamics of Cardiogenic Shock Navin K. Kapur, Boston, MA 11:15 AM Evaluating HFpEF in the Cath Lab Barry A. Borlaug, Rochester, MN 11:30 AM Evaluating Pulmonary Hypertension Paul R. Forfia, Philadelphia, PA 11:45 AM Assessing the Right Ventricle: Best Practices Gregory D. Lewis, Boston, MA 12:00 PM Adjourn Learning objective: Describe the role of hemodynamics in heart failure and its management. 10:00 AM – 12:00 PM Milano III Contemporary Issues in Pulmonary Hypertension Moderators: Sean P. Pinney, New York, NY Ioana Preston, Boston, MA 10:00 AM Molecular Pathways In The Development of Pulmonary Hypertension Ioana Preston, Boston, MA 10:20 AM Genetic Determinants of Pulmonary Hypertension: When is Testing Appropriate? Anna R. Hemnes, Nashville, TN 10:40 AM Evaluation and Treatment of Pulmonary Arterial Hypertension Teresa De Marco, San Diego, CA 11:00 AM Evaluation and Management of Pulmonary Hypertension in HFrEF Jonathan D. Rich, Chicago, IL 11:20 AM Evaluation and Management of Pulmonary Hypertension in HFpEF Sanjiv J. Shah, Chicago, IL 11:40 AM Panel Discussion Faculty 12:00 PM Adjourn Learning objective: Describe the causes and effective management of pulmonary hypertension in HFrEF and HFpEF. 10:00 AM – 12:00 PM Milano VII Heart Failure Palliative Care: Critical Issues


Moderators: Erin K. Donaho, Houston, TX Nancy M. Albert, Cleveland, OH 10:00 AM Managing the Patient through the HF Trajectory—Chronic Disease to End of Life Erin K. Donaho, Houston, TX 10:20 AM The Role of Palliative Care in Heart Transplant and LVAD Evaluations Deborah Meyers, Houston, TX 10:40 AM Palliative Care Pearls for the Heart Failure Team Ellin F. Gafford, Columbus, OH 11:00 AM Why Don't Patients Know They Have Heart Failure? The Role of Communication from

Diagnosis to Death Beth Fahlberg, Madison, WI 11:20 AM Inotropes for Palliation of Advanced Heart Failure Symptoms Nita Meaux, Houston, TX 11:40 AM Where Are We with Operationalizing the Guidelines for End of Life Care? Sarah J. Goodlin, Portland, OR 12:00 PM Adjourn Learning objective: Use effective communication and management strategies to provide palliative care for HF patients. Abstracts/posters of interest: 145, 146, 150, 165, 303 12:00 PM – 2:30 PM Neapolitan I Hands-‐on Workshop on CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting (Limited enrollment, pre-‐registration required) Chair: Jagmeet Singh, Boston, MA Learning objective: Describe indications for CRT, identify devices used in CRT, demonstrate their use and interrogation,

data interpretation, and troubleshooting. 12:30 PM – 2:30 PM Milano I Satellite Symposium: TBD [Right Ventricle?] 3:00 PM – 5:30 PM Milano III-‐IV Can We Prevent Heart Failure? (AHA Joint Session) Moderators: Javed Butler, Atlanta, GA Marvin A. Konstam, Boston, MA 3:00 PM Risk Assessment Beyond Comorbidities: Detecting and Defining Stage A Wayne C. Levy, Seattle, WA 3:20 PM Prevention of Heart Failure: What’s New with Hypertension? Clyde W. Yancy, Chicago, IL 3:40 PM Lifestyle Management to Reduce Heart Failure Risk: Is There a Role? Luc Djousse, Boston, MA 4:00 PM Management of Diabetes and Heart Failure Risk Biykem Bozkurt, Houston, TX 4:20 PM Evaluation Before and Monitoring After Chemotherapy Douglas B. Sawyer, Nashville, TN 4:40 PM What Is the Role of Genetic Testing and Family Screening? Ray E. Hershberger, Columbus, OH 5:00 PM Panel Discussion


Faculty 5:30 PM Adjourn Learning objective: Use effective strategies to identify risks and and provide counseling to prevent HF. 3:00 PM – 5:30 PM Milano V Challenges in Caring for the Elderly Patient with a VAD (ICCAC-‐VAD Joint Session) Moderators: Michael G. Petty, Minneapolis, MN Tonya Elliott, Fairfax, VA 3:00 PM Selection, Frailty and Outcomes: Destination Therapy in the Elderly Karl Nelson, Oklahoma City, OK 3:20 PM When Are You Too Old for Heart Transplant and Just Right for LVAD Therapy? Joseph G. Rogers, Durham, NC 3:40 PM LVAD Evaluation of the Elderly Patient: Special Considerations Pamela S. Combs, Seton, TX 4:00 PM Coordinating the Care of the Elderly Patient Following LVAD Implantation Tonya Elliott, Fairfax, VA 4:20 PM Break 4:30 PM Elders Caring for Elders: Supporting the Elder Caregiver Michael G. Petty, Minneapolis, MN 4:50 PM Rehabilitating Elderly Patients—How It’s the Same, How It’s Different Justin Canada, Richmond, VA 5:10 PM Bridge or Destination Therapy—Managing the Bridge-‐to-‐Decision Patient Jeffrey J. Teuteberg, Pittsburgh, PA 5:30 PM Adjourn Learning objective: Describe the challenges of elderly patients with VADs and strategies for effective management. 3:00 PM – 5:30 PM Milano VII Excellence in Basic Science: Translational Targets Move to the Clinic Moderators: Maria I. Kontaridis, Boston, MA Mark A. Sussman, San Diego, CA 3:00 PM Tyrosine Kinase Inhibitors Exacerbate Post MI Remodeling Steven R. Houser, Philadelphia, PA 3:30 PM GRK as a Novel Translational Target in Heart Failure Treatment Walter J. Koch, Philadelphia, PA 4:00 PM Inhibition of G-‐protein Signaling in Treating Human Heart Failure Burns C. Blaxall, Cincinnati, OH 4:30 PM MAPK Inhibitory Strategies in Treating Human Heart Disease L Kristin Newby, Durham, NC 5:00 PM TroponinI3kinase in the Heart… and Elsewhere? Thomas L. Force, Nashville, TN 5:30 PM Adjourn Learning objective: Describe progress in the potential use novel treatment targets in HF. Abstracts/posters of interest: 062, 064, 065, 066, 067, 204, 207, 208 3:00 PM – 5:30 PM Milano I Hemodynamic Impact of Drugs and Devices (SCAI Joint Session)


Moderators: Navin K. Kapur, Boston, MA Richard Ha, Stanford, CA 3:00 PM Hemodynamics of Continuous Flow LVADs Nir Uriel, Chicago, IL 3:20 PM Invasive Hemodynamics and LVAD Dysfunction Atman Shah, Chicago, IL 3:40 PM Low Output Aortic Stenosis: What to do in the TAVR Era Paul Sorajja, Minneapolis, MN 4:00 PM Closing One Door Opens Another: Interventions for Functional MR Ramesh Daggubati, Greenville, NC 4:15 PM Complicated Hypotension Jose N. Nativi Nicolau, Salt Lake City, UT 4:30 PM Hemodynamics of RV Failure Susan Joseph, St. Louis, MO 4:45 PM Temporary Mechanical Support in an Advanced Heart Failure Program Navin K. Kapur, Boston, MA 5:00 PM Multi-‐vessel Revascularization in Advanced Heart Failure Frederick G Welt, Salt Lake City, UT 5:15 PM Panel Discussion Faculty 5:30 PM Adjourn Learning objective: Identify the hemodynamic impact of drugs and devices on HF; describe management strategies. 3:00 PM – 5:30 PM Neapolitan I Hands-‐on Workshop on CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting (Limited enrollment, pre-‐registration required) Chair: Jagmeet Singh, Boston, MA Learning objective: Describe indications for CRT, identify devices used in CRT, demonstrate their use and interrogation,

data interpretation, and troubleshooting. 6:00 PM – 8:00 PM Exhibit Hall Opening Reception and Poster Reception Presenters at their posters: 6:30 -‐7:30


MONDAY, SEPTEMBER 15 6:30 AM – 7:30 AM Milano Foyer Light Breakfast 7:00 AM – 8:00 AM Milano III Satellite Symposium: Hyponatremia in Heart Failure: Incorporating Practice Recommendations into Clinical Practice Chair: Steven Goldsmith, Minneapolis, MN 7:00 AM The Scope of the Problem and Guidelines Steven R. Goldsmith, Minneapolis, MN 7:05 AM Pathophysiology of Dilutional Hyponatremia, Including Symptoms of Mild to Moderate

Hyponatremia Joseph G. Verbalis, Washington, DC 7:20 AM Prognostic Implications of Hyponatremia, Potential Mechanisms of Causation Paul J. Hauptman, St. Louis, MO 7:35 AM Putting Guidelines into Practice: Cases From the Real World Linda Ordway, Boston, MA 7:50 AM Panel Discussion Faculty 8:00 AM Adjourn Learning Objectives: 1. Identify guideline recommendations on the treatment of patients with hyponatremia 2. Describe the pathophysiology of dilutional hyponatremia, including symptoms of mild to moderate hyponatremia 3. Describe the prognostic implications of hyponatremia and potential causal mechanisms 4. Apply evidence-‐based therapy to cases of patients with heart failure and hyponatremia Supported by an educational grant from Otsuka America Pharmaceuticals, Inc. 7:00 AM – 8:00 AM Milano VII Satellite Symposium: Imaging Sympathetic Innervation in Heart Failure: Window into Pathology and Outcome Chair: Barry A. Greenberg, San Diego, CA 7:00 AM Welcome and Introduction Barry H. Greenberg, San Diego, CA 7:05 AM A Primer on Imaging Innervation in Heart Failure Patients: How Is It Performed and

Analyzed? Matthew J. Budoff, Los Angeles, CA 7:20 AM The Role of MIBG Imaging in Heart Failure Risk Assessment Wayne C. Levy, Seattle, WA 7:35 AM Clinical Scenarios to Consider Imaging for Informing Challenging Decisions in the Clinic Barry H. Greenberg, San Diego Faculty 7:50 AM Panel Discussion Faculty 8:00 AM Adjourn


Learning Objectives: 1. Describe the role of sympathetic hyperactivity in heart failure progression 2. Describe how MIBG imaging works and how it is analyzed 3. Identify the prognostic value of MIBG imaging alone and in conjunction with other risk assessment measures in

patients with heart failure. 4. Outline the possible use of MIBG imaging to enhance assessment of individual patients Supported by an educational grant from GE Healthcare 7:00 AM – 8:00 AM Milano V Satellite Symposium: o Chair: Philip B. Adamson, Oklahoma City, OK 7:00 AM Welcome and Introduction Phiip B. Adamson, Oklahoma City, OK 7:05 AM Overview of Remote Monitoring of Heart Failure Patients Phiip B. Adamson, Oklahoma City, OK 7:20 AM Review of Clinical Trials of Implantable Hemodynamic Monitoring William T. Abraham, Columbus, OH 7:35 AM Putting Implantable Hemodynamic Monitoring into Practice Sara C. Paul, Hickory, NC 7:50 AM Panel Discussion Faculty 8:00 AM Adjourn Learning objectives: 1. Describe the goals and obstacles of remote monitoring of patients with heart failure 2. Discuss the findings of clinical trials of implantable hemodynamic monitoring 3. Outline the process of using implantable hemodynamic monitoring in practice 4. Identify patient scenarios in which implantable hemodynamic monitoring could play a role in improving treatment

and reducing hospitalizations Supported by an educational grant from St. Jude Medical 8:05 AM – 10:00 AM Augustus I 8:05 AM Opening Remarks Michele Blair, Chevy Chase, MD 8:10 AM Lifetime Achievement Award Presented by Jay N. Cohn, Minneapolis, MN 8:20 AM Outgoing President's Address Thomas L. Force, Nashville, TN Plenary Session: The Challenge of Care Disparities in Heart Failure Moderators: Monica Colvin, Minneapolis, MN Clyde W. Yancy, Chicago, IL 8:30 AM Racial/Ethnic Disparities and Cross Cultural Care: The Role of Academic Centers Joseph R. Betancourt, Boston, MA 8:55 AM Future Policy Strategies to Eliminate Disparities in Care Bruce Siegel, Washington, DC 9:20 AM Bridging the Gap for Heart Health Disparities in Women


Nakela L. Cook, Bethesda, MD 9:45 AM Panel Discussion Robert C. Like, New Brunswick, NJ 10:00 AM Adjourn Learning objective: Describe care disparities in HF and identify strategies to reduce or eliminate them. 10:30 AM – 12:00 PM Milano III Controversies and Challenges in Device Therapy (HRS Joint Session) Moderators: Linda K. Ottoboni, Stanford, CA Jagmeet Singh, Boston, MA 10:30 AM Redefining Indications for CRT: Are They Shrinking or Expanding? Leslie A. Saxon, Los Angeles, CA 10:50 AM Enhancing Response in the CRT Non-‐Responder Kimberly A. Parks, Boston, MA 11:10 AM Device Therapy for Autonomic Modulation in the Heart Failure Patient: The Next Era

for Devices? Philip B. Adamson, Oklahoma City, OK 11:30 AM Managing Pacing and Shocks to Improve Long-‐Term Outcomes in the Heart Failure

Patient Ronald D. Berger, Baltimore, MD 11:50 AM Panel Discussion Faculty 12:00 PM Adjourn Learning objective: Identify challenges in the use of devices to manage heart failure; describe effective response

strategies. Abstracts/posters of interest: 089, 111, 143, 144, 152, 167, 177, 288, 304, 313 10:30 AM – 12:00 PM Augustus I Heart Failure Trials: The Year in Review Moderators: William T. Abraham, Columbus, OH Eugene S. Chung, Cincinnati, OH 10:30 AM TOPCAT Bertram Pitt, Ann Arbor, MI 10:50 AM ROSE-‐AHF Horng H. Chen, Rochester, MN 11:10 AM CTSN – MR Michael A. Acker, Philadelphia, PA 11:30 AM EXACT Michael M. Givertz, Boston, MA 11:50 AM Panel Discussion Faculty 12:00 PM Adjourn Learning objective: Outline key findings of recent key trials in heart failure and their potential impact on practice. 10:30 AM – 12:00 PM Milano VIII Predicition Is Hard, Especially About the Future: Dealing with Uncertainty in Risk Assessment


Moderators: Larry A. Allen, Denver, CO Eldrin F. Lewis, Boston, MA 10:30 AM Considering Risk for Outcomes other than Survival Kathleen Grady, Chicago, IL 10:45 AM Quantifying Uncertainty in Risk Models Larry A. Allen, Denver, CO 11:00 AM Standardized Methods for Transmitting Uncertain Risk Estimates Shane J. LaRue, St. Louis, MO 11:15 AM Grappling with Uncertainty in Discussions with Patients and Families Sara E. Wordingham, Scottsdale, AZ 11:30 AM Case Discussion Eldrin F. Lewis, Boston, MA 12:00 PM Adjourn Learning objective: Describe the role of uncertainty in determining risk and how to approach uncertainty in clinical

communication. Abstract/posters of interest: 049, 059, 075, 080, 087, 115, 124, 133, 137, 143, 146, 147, 175, 197, 226, 253, 263, 266, 267, 273, 275, 283, 287, 310 10:30 AM – 12:00 PM Milano VII Venous Congestion in Heart Failure: The Dark Side of the Moon Moderators: John C. Burnett Jr., Rochester, MN Maria Rosa Costanzo, Naperville, IL 10:30 AM Development of the Cardiorenal Syndrome in Heart Failure: Epidemiology and

Outcomes Stephen S. Gottlieb, Baltimore, MD 10:45 AM The Role of Venous Congestion in the Pathophysiology of Acute Heart Failure Paolo C. Colombo, New York, NY 11:00 AM Abdominal Contributions to Renal Dysfunction in Heart Failure Wilfried Mullens, Diepenbeek, Belgium 11:15 AM Hemodynamic Determinants of Dynamic Changes in Serum Creatinine in Acute

Decompensated Heart Failure W.H. Wilson Tang, Cleveland, OH 11:30 AM Hemoconcentration as a Treatment Goal in Acute Heart Failure Jeffrey M. Testani, New Haven, CT 11:45 AM Panel Discussion Faculty 12:00 PM Adjourn Learning objective: Describe the role of venous congestion in heart failure and its management. 10:30 AM -‐ 1:00 PM Neapolitan I Hands-‐on Workshop: Acute Management of Cardiogenic Shock with Peripherally Implanted Devices (Limited enrollment, preregistration required) Chair: Navin K. Kapur, Boston, MA Learning objective: Describe management goals in cardiogenic shock, identify percutaneous devices used in the

management of cardiogenic shock, and demonstrate their uses.


12:15 PM – 1:15 PM Milano VII How to Develop a Comprehensive Heart Failure Clinic in a Community Setting Kathleen Halvey, Atlanta, GA Lee W. Jordan, Columbus, OH David L. Smull, Winston-‐Salem, NC Learning objective: Identify the challenges and components of a successful HF clinical in a community setting. 12:15 PM -‐1:15 PM Milano V How to Use Biomarkers in Clinical Practice James L. Januzzi, Boston, MA Alan S. Maisel, San Diego, CA Learning objective: Use biomarkers effectively to assist in the diagnosis and management of HF. 12:15 PM – 1:15 PM Milano VIII How to Assess Frailty and Make Appropriate Activity Recommendations Susan Joseph, St. Louis, MO Ileana L. Pina, New York, NY Learning objective: Describe methods for effectively assessing frailty and making activity recommendation for patients

with HF. 12:15 PM – 1:15 PM Milano I How to Diagnose and Treat LVAD Complications Sirtaz Adatya, Minneapolis, MN Jason N. Katz, Chapel Hill, NC Jonathan D. Rich, Chicago, IL Learning objective: Use effective methods to identify and manage LVAD complications in patients with HF. 12:15 PM – 1:15 PM Milano III Rapid Fire Abstracts I Moderators: Steven R. Houser, Philadelphia, PA Mark H. Drazner, Houston, TX LVAD and Transplant 12:15 PM Comparison of Readmission Causes and Rates in Patients Supported with an Axial

versus Centrifugal Flow LVAD Carolyn M. Rosner, Palak Shah, Erica Lin, Anthony J. Rongione. Inova Health System, Falls Church, VA 12:20 PM Single Center Experience with Implantation of Permanent LVADs after VA ECMO

Bridge in Patients with Acute Cardiogenic Shock Sandeep M. Jani, Farooq H. Sheikh, Farnoosh Rahimi, David T. Majure, Mark Hoymeyer, George Ruiz, Samer S. Najjar, Steven Boyce, Ezequiel J. Molina. Medstar Heart Institute, Washington, DC


12:25 PM Decreased Cardiac Allograft Survival in Patients Transplanted for Alcohol-‐Induced Cardiomyopathy: Data from the United Network for Organ Sharing (UNOS) Registry

Sadeer Al-‐Kindi, Marwan Qattan, Joyce Ngoroge, Chantal ElAmm, Mahazarin Ginwalla, Guilherme H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH 12:30 PM Cardiac Arrhythmias in Patients with a HeartWare Ventricular Assist Device Salpy V. Pamboukian1, Mark S. Slaughter2, Howard K. Song3, Charles T. Klodell4, David R. Hathaway5, Keith D. Aaronson6. 1University of Alabama at Birmingham, Birmingham, AL; 2University of Louisville, Louisville, KY; 3Oregon Health and Science University, Portland, OR; 4University of Florida Health, Gainesville, FL; 5Heartware Inc, Framingham, MA; 6University of Michigan Medical Center, Ann Arbor, MI 12:35 PM Annual Screening with Select Coronary Angiography for Cardiac Allograft Vasculopathy

(CAV) is Unnecessary in the Presence of a Normal Dobutamine Stress Echocardiography (DSE)

Carlos M. Orrego, Andrea M. Cordero-‐Reyes, Cesar Uribe, Arvind Bhimaraj, Barry H. Trachtenberg, Guha Ashrith, Guillermo Torre-‐Amione, Jerry D. Estep. Houston Methodist Hospital, Houston, TX 12:40 PM Late Antibody-‐Mediated Rejection (AMR) in Heart Transplantation: How “Late” Is It? Jennifer L. Nixon, Gregory L. Snow, Deborah Budge, M. E. Hammond, Joseph Stehlik, Bruce Reid, Rami A. Alharethi, Dylan V. Miller, Melanie D. Everitt, Stephen H. McKellar, M. P. Revelo, James C. Fang, Abdallah G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT New Therapies 12:45 PM Single Center Experience with Outpatient Continuous Infusion of Positive Inotropic

Therapy Ahmad Hamad1,2, George Ruiz1, Farooq Sheikh1, David Majure1, Michelle Michaels1, Eulalia Callahan1, Samer Najjar1. 1MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC; 2American University of Beirut Medical Center, Beirut, Lebanon 12:50 PM Short (2 Hour) Intravenous Infusion of Purified Poloxamer 188 (MST-‐188) Elicits

Prolonged (1-‐2 Weeks) Improvement in LV Ejection Fraction and Suppresses Elevations of Plasma Troponin-‐I and nt-‐pro Brain Natriuretic Peptide in Dogs with Advanced Heart Failure

Hani N. Sabbah1, Ramesh C. Gupta1, Mengjun Wang1, Kefei Zhang1, Sharad Rastogi1, Marty Emanuele2. 1Henry Ford Health System, Detroit, MI; 2Mast Therapeutics, Inc., San Diego, CA 12:55 PM Clinical Implications of The PR interval in Patients Hospitalized for Worsening Heart

Failure and Reduced Ejection Fraction: Analysis of The EVEREST Study Benjamin S. Wessler1, Haris Subacius2, Mihai Gheorghiade3, Marvin A. Konstam1, Faiez Zannad4, James Udelson1. 1Tufts Medical Center, Boston, MA; 2Northwestern University Feinberg School of Medicine, Chicago, IL; 3Northwestern University Feinberg School of Medicine, Chicago, IL; 4Université de Lorraine, Nancy, France 1:00 PM Clinical and Pathologic Characteristics and Predictors of Myocarditis and Recovery in

Patients Undergoing Endomyocardial Biopsy for Acute Onset Heart Failure Nisha A. Gilotra1, Mosi K. Bennett2, Adam Shpigel1, Haitham M. Ahmed1, Marc K. Halushka1, Stuart D. Russell1. 1Johns Hopkins Hospital, Baltimore, MD; 2Minneapolis Heart Institute Foundation, Minneapolis, MN 1:05 PM Riociguat for HF with Pulmonary Hypertension (PH): Post-‐hoc Analysis of LEPHT by

Baseline Pulmonary Vascular Resistance (PVR) and Pulmonary Vascular Gradient (PVG) Diana Bonderman1, Stefano Ghio2, Stephan B. Felix3, Hossein-‐Ardeschir Ghofrani4, Evangelos Michelakis5, Veselin Mitrovic6, Ronald J. Oudiz7, Francis Boateng8, Lothar Roessig9, Marc J. Semigran10. 1Medical University of Vienna, Vienna, Austria; 2University Hospital, Pavia, Italy; 3University Medicine Greifswald, Greifswald, Germany; 4University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; 5University of Alberta, Edmonton, AB, Canada; 6Kerckhoff-‐Klinik Forschungsgesellschaft GmbH, Bad Nauheim, Germany; 7Los Angeles Biomedical Research Institute at Harbor-‐UCLA Medical Center, Torrance, CA; 8Bayer HealthCare


Pharmaceuticals, New York, NY; 9Bayer Pharma AG, Berlin, Germany; 10Harvard Medical School, Boston, MA 1:10 PM SDF-‐1 Plasmid Attenuates Adverse Remodeling in Ischemic Heart Failure Patients in a

Randomized Phase II Trial Eugene S. Chung1, Marc S. Penn2, Warren Sherman3, R. David Anderson4, Farrell O. Mendelsohn5, Scott J. Fisher6, Joseph M. Pastore6, Rahul Aras6, Leslie Miller7, Amit N. Patel8. 1The Linder Center, Cincinnati, OH; 2Summa Cardiovascular Institute, Akron, OH; 3Columbia University, New York, NY; 4University of Florida, Gainesville, FL; 5Center for Therapeutic Angiogenesis, Birmingham, AL; 6Juventas Therapeutics, Inc, Cleveland, OH; 7Pepin Heart, Tampa, FL; 8University of Utah, Salt Lake City, UT 1:15 PM Adjourn Learning objective: Discuss recent research in LVAD, transplant, and new therapies in HF and their implications for clinical

practice. 1:30 PM – 3:00 PM Milano I Guideline Session: Defining Advanced Heart Failure to Anticipate Prognosis and Guide Therapy Moderators: Michael M. Givertz, Boston, MA Lynne Warner Stevenson, Boston, MA 1:30 PM Limitations of Current Definitions and Guidelines Gregory A. Ewald, St. Louis, MO 1:45 PM NYHA, WHO, INTERMACS, etc: Which Profile, Which Patient? Garrick C. Stewart, Boston, MA 2:00 PM Cardiorenal and Cardiohepatic Interactions Meredith A. Brisco, Charleston, SC 2:15 PM Role of Percutaneous VADs in Clarifying the Destination Srihari S. Naidu, Mineola, NY 2:30 PM Malnutrition and Right Heart Failure: Chicken or Egg? Nancy K. Sweitzer, Tucson, AZ 2:45 PM Frailty and Sacopenia in Older Patients with Advanced Heart Failure Miles D. Witham, Dundee, UK 3:00 PM Adjourn Learning objective: Identify limitations of current definitions of advanced HF and describe key treatment considerations. Abstracts/posters of interest: 070, 098, 121, 123, 136, 146, 150, 151, 159, 162, 219, 243, 263, 303, 310 1:30 PM – 3:00 PM Milano VIII Heart Failure in Adults with Congenital Heart Disease Moderators: Luke J. Burchill, Portland, OR Karen K. Stout, Seattle, WA 1:30 PM Types of Congenital Abnormalities and Surgical Interventions Leading to Heart Failure John Lynn Jefferies, Cincinnati, OH 1:45 PM The Etiology and Prevalence of Heart Failure in Adults with Congenital Heart Disease Sasha Opotowsky, Boston, MA 2:00 PM Current Approach to Medical Therapy in the Congenital Heart Patient Karen K. Stout, Seattle, WA 2:15 PM Surgical Support for Failing Congenital Heart Patients: Obstacles and Solutions to

VADs Joshua L. Hermsen, Seattle, WA 2:30 PM Transplant Outcomes in Patients with Congenital Disease: Who Does Well or Poorly,

and Why?


Luke J. Burchill, Portland, OR 2:45 PM Panel Discussion Faculty 3:00 PM Adjourn Learning objective: Describe HF in adults with congenital heart disease and current therapeutic approaches. Abstracts/posters of interest: 164, 182, 184, 186, 192 1:30 PM – 3:00 PM Milano V-‐VI Heart Failure in Cancer Patients and Survivors: Prevention, Monitoring and Management Moderators: Jean-‐Bernard Durand, Houston, TX Alan T. Kono, Lebanon, NH 1:30 PM Molecular Mechanisms of Cardiotoxicity Edward TH Yeh, Houston, TX 1:45 PM Chemotherapy-‐ Associated Heart Failure: How Often Does It Really Occur and Can It

Be Prevented? Ronald M. Witteles, Stanford, CA 2:00 PM Early Detection and Monitoring for the Development of Cardiomyopathy and Survivors Daniel J. Lenihan, Nashville, TN 2:15 PM Survivorship Programs Steven Lipshultz, Detroit, MI 2:30 PM Interdisciplinary Approach for the Management of Heart Failure in Cancer Patients Anecita P. Fadol, Houston, TX 2:45 PM Panel Discussion Faculty 3:00 PM Adjourn Learning objective: Describe cardiotoxicity in cancer patients and survivors; employ interdisciplinary management

strategies. 1:30 PM – 3:00 PM Milano VII Update on Stem Cell Clinical Trials Moderators: Joshua M. Hare, Miami, FL Jop van Berlo, Minneapolis, MN 1:30 PM Trial Update: Is Cell Therapy Beneficial in Dilated Cardiomyopathy? Joshua M. Hare, Miami, FL 1:45 PM Update from Cardiovascular Cell Therapy Research Network (CCTRN) Roberto Bolli, Louisville, KY 2:00 PM Do Endogenous Cardiac ckit Cells Really Make New Myocytes? Jop van Berlo, Minneapolis, MN 2:15 PM Cardiac iPSCs: Clinical Trial in a Dish Joseph Wu, Stanford, CA 2:30 PM Next-‐generation Clinical Trials with Cardiosphere-‐derived Cells Eduardo Marban, Los Angeles, CA 2:45 PM Translational Perspective from Animal Models with cKit Stem Cells Annarosa Leri, Boston, MA 3:00 PM Adjourn Learning objective: Describe the current status of research in stem cell therapy in cardiovascular disease. 1:30 AM -‐ 4:00 PM


Neapolitan I Hands-‐on Workshop: Acute Management of Cardiogenic Shock with Peripherally Implanted Devices (Limited enrollment, preregistration required) Chair: Navin K. Kapur, Boston, MA Learning objective: Describe management goals in cardiogenic shock, identify percutaneous devices used in the

management of cardiogenic shock, and demonstrate their uses. 3:30 PM – 5:00 PM Milano VIII Central Congestion in Obesity: Is the Heart an Innocent Bystander? Moderators: Thomas P. Cappola, Philadelphia, PA Stuart D. Katz, New York, NY 3:30 PM Cardiovascular Effects of Adipokines Gary Sweeney, Toronto, ON, CA 3:50 PM Cardiopulmonary Effects of Obesity Beno Oppenheimer, New York, NY 4:10 PM Hemodynamic Effects of Obesity Martin A. Alpert, Columbia, MO 4:30 PM Sarcopenic Obesity and Exercise Intolerance in Heart Failure Dalane W. Kitzman, Winston-‐Salem, NC 4:50 PM Panel Discussion Faculty 5:00 PM Adjourn Learning objective: Describe the effects of obesity in heart failure and its impact on management options. Abstracts/posters of interest: 51, 147 3:30 PM – 5:00 PM Augustus I Late Breaking Clinical Trials Moderators: Prakash Deedwania, San Francisco, CA Christopher M. O'Connor, Durham, NC 3:30 PM STEP-‐WISE: A Phase 2b Study Comparing Cross-‐linked Phyloelectrolyte (CLP) with

Placebo in Heart Failure Subjects John Cleland, Harefield Middlesex, UK 3:40 PM Commentary Javed Butler, Atlanta, GA 3:45 PM Autonomic Regulation Therapy to Enhance Myocardial Function in Heart Failure

(ANTHEM-‐HF) Study Inder A. Anand, Minneapolis, MN 3:55 PM Commentary Jagmeet Singh, Boston, MA 4:00 PM Maintenance of Normokalemia with ZS-‐9 Once Daily in CHF Patients on RAAS

Inhibitors Mohamed A. El-‐Shahawy, Los Angeles, CA 4:10 PM Commentary Stephen Gottlieb, Baltimore, MD 4:15 PM Percutaneous Ventricular Restoration (PVR) Therapy Using the Parachute® Device in

Patients with Ischemic Dilated Heart Failure: PARACHUTE III, European Post Market Trial-‐-‐Primary Endpoint Results


William T. Abraham, Columbus, OH 4:25 PM Commentary James C. Fang, Salt Lake City, UT 4:30 PM Serum Potassium Reduction and Prevention of Recurrent Hyperkalemia with

Patiromer in Patients with Heart Failure and Chronic Kidney Disease on RAAS Inhibitors

Bertram Pitt, Ann Arbor, MI 4:40 PM Commentary Mark Drazner, Dallas, TX 4:45 PM Prospective Comparison of ARNI with ACEI to Determione Impact on Global Mortality

and Morbidity in Heart Failure Trial (PARADIGM-‐HF) Milton Packer, Dallas, TX 4:55 PM Commentary Lynne Warner Stevenson, Boston, MA 5:00 PM Adjourn Learning objective: Describe results from current key research in heart failure and their implications for practice. Abstracts/posters of interest: 97, 105, 233, 238, 241, 244, 319, 320, 321, 322 3:30 PM – 5:00 PM Milano V Trends and Treatment Options for LVAD Thrombosis Moderators: Michael A. Acker, Philadelphia, PA Stuart D. Russell, Baltimore, MD 3:30 PM Incidence and Prevalence of Thrombosis in Continuous Flow LVADs Randall C. Starling, Cleveland, OH 3:45 PM Potential Factors Related to the Rise in Thrombosis Rates: What Happened? Mandeep R. Mehra, Boston, MA 4:00 PM Is There a Difference Between Continuous Flow LVADs? Jeffrey J. Teuteberg, Pittsburgh, PA 4:15 PM Diagnosis of LVAD Thrombosis: Is LDH the Best Biomarker? Gregory A. Ewald, St. Louis, MO 4:30 PM Treatment Options for Pump Thrombosis: Anticoagulation, Exchange or Transplant Michael S. Kiernan, Boston, MA 4:45 PM Panel Discussion Faculty 5:00 PM Adjourn Learning objective: Describe the incidence and prevalence of thrombosis in continuous flow LVADs, factors related to their

increase, and treatment options. 3:30 PM – 5:00 PM Milano VII Why the First Six Hours Are Not Like the Next 18 Hours (SAEM Joint Session) Moderators: Sean P. Collins, Nashville, TN Phillip D. Levy, Detroit, MI 3:30 PM The Importance of Early Management in the ED Deborah B. Diercks, Sacramento, CA 3:45 PM What Have We Learned from Recent Acute Heart Failure Trials? John R. Teerlink, San Francisco, CA 4:00 PM Acute Management in the Observation Unit: The Ideal Patient and Ideal Location Peter S. Pang, Chicago, IL 4:15 PM ED Guidelines for Heart Failure: What Are They? Do They Need to Change?


Gregg C. Fonarow, Los Angeles, CA 4:30 PM Not Your Typical Consent: Successful ED Clinical Trial Enrollment Gregory J. Fermann, Cincinnati, OH 4:45 PM Panel Discussion Faculty 5:00 PM Adjourn Learning objective: Describe the role of the emergency department in the treatment of HF and the importance of early

treatment. Abstracts/posters of interest: 095, 097,153, 266, 297, 309, 313, 314 5:00 PM – 6:30 PM Exhibit Hall Poster Reception Presenters at posters 5:30-‐6:30 PM. 7:00 PM – 9:00 PM Roman Ballroom Faculty Reception and Dinner (Everyone is invited. Tickets can be purchased at the registration desk.)


TUESDAY, SEPTEMBER 16 6:30 AM – 7:30 AM Milano Foyer Light Breakfast 7:00 AM – 8:00 AM Milano III Satellite Symposium: Managing Hyperkalemia in Heart Failure: A Shifting Paradigm? Chair: Marvin A. Konstam, Boston, MA 7:00 AM Welcome and Introduction Marvin A. Konstam, Boston, MA 7:05 AM Balancing the Benefits of HF Therapy With Risk of Hyperkalemia Domenic A. Sica, Richmond, VA 7:25 AM Insights into Novel Therapy for Hyperkalemia Gregg C. Fonarow, Los Angeles, CA 7:45 AM Shifting the Paradigm of Hyperkalemia Management: Is It Necessary? Faculty Panel Discussion Moderator: Marvin A. Konstam 8:00 AM Adjourn Learning Objectives: 1. Describe the prevalence, etiology and pathogenesis of hyperkalemia in HF 2. Identify strategies for optimizing HF treatment and balancing risk of hyperkalemia 3. Cite the benefits and limitations of current treatment strategies for acute and chronic hyperkalemia 4. Compare and contrast the efficacy and safety of novel investigational therapies for hyperkalemia Supported by an educational grant from ZS Pharma. 7:00 AM – 8:00 AM Milano V Satellite Symposium: Heart Failure Patients with Mitral Regurgitation: New Guidelines, New Options Chair: JoAnn Lindenfeld, Aurora, CO 7:00 AM Welcome and Introduction JoAnn Lindenfeld, Aurora, CO 7:05 AM Functional Mitral Regurgitation: Definitions, Causes, Natural HIstory Eric Velazquez, Durhan, NC 7:20 AM Remodeling of the Mitral Valve Jonathan Beaudoin, Montreal, QC, Canada 7:35 AM Percutaneous Therapies for Mitral Regurgitation: Where We Are Now Michael Kim, Aurora, CO 7:50 AM Panel Discussion Faculty 8:00 AM Adjourn Learning objectives: 1. Define specific types of mitral regurgitation 2. Identify guidelines for the management of mitral regurgitation (MR) in patients with heart failure 3. Describe remodeling of the mitral valve


4. Define surgical risk in patients with MR and heart failure 5. Identify treatment options for patients with MR and heart failure 6. Discuss emerging therapeutic options in the treatment of patients with MR and heart failure Supported by an educational grant from Abbott Vascular. 7:00 AM – 8:00 AM Milano I Clinical Fundamentals II: Beyond Peak Oxygen Consumption: New Insights into Cardiopulmonary Exercise Testing Moderators: Donna M. Mancini, New York, NY Marc J. Semigran, Boston, MA 7:00 AM The Basics of CPET: Test Performance, Pitfalls and Interpretation Donna M. Mancini, New York, NY 7:15 AM Heart Failure and Lung Disease: Differentiating the Relative Roles of Cardiac and

Pulmonary Reserve Bradley Maron, Boston, MA 7:30 AM The Importance of VE/VCO2, Exercise Oscillatory Ventilation, and Oxygen Debt

Recovery Gregory D. Lewis, Boston, MA 7:45 AM CPET in Evaluating the HF Patient for Mechanical Support and Transplantation Stuart D. Russell, Baltimore, MD 8:00 AM Adjourn Learning objective: Describe the role of cardiopulmonary exercise testing in HF assessment and management. 8:10 AM – 10:00 AM Augustus I-‐II 8:10 AM Clinical Excellence in Nursing Award Robin J. Trupp, Durham, NC Nursing Leadership Award Corrine Y. Jurgens, Stony Brook, NY 8:15 AM Incoming President's Address JoAnn Lindenfeld, Denver, CO Plenary Session: Comparative Effectiveness Research: The Time Has Come Moderators: Marvin A. Konstam, Boston, MA Mary N. Walsh, Indianapolis, IN 8:30 AM The Future of Comparative Effectiveness Research in the US Robert M. Califf, Durham, NC 8:55 AM Comparative Effectiveness Research in Heart Failure Adrian F. Hernandez, Durham, NC 9:20 AM Can Comparative Effectiveness Research Be Accomplished with Observational

Models? Paul D. Varosy, Denver, CO 9:45 AM Panel Discussion Faculty 10:00 AM Adjourn Learning objective: Describe comparative effectiveness research and how it could impact the treatment of HF. 10:00 AM – 12:00 PM


Neapolitan I Hands-‐on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices Chair: Joseph Rogers, Durham, NC Learning objective: Identify durable VADs, demonstrate their use, and describe effective patient selection, management,

and troubleshooting. Abstracts/posters of interest: 68, 69, 70, 75, 77, 79, 80, 81, 82, 83, 84, 86, 133, 141, 209, 212, 214, 216, 217, 218, 219, 220, 222, 224, 225, 226, 227, 280, 280, 284, 301, 312 10:30 AM – 12:00 PM Milano I-‐II Case Discussion Moderators: Marie Galvao, New York, NY Paul J. Mather, Philadelphia, PA Discussion Panel Karol Harshaw-‐Ellis, Durham, NC Gina G. Mentzer, Columbus, OH Jean M. Nappi, Charleston, SC Mitchell T. Saltzberg, Newark, DE William G. Stevenson, Boston, MA 10:30 AM Case 1:

75 y/o male with h/o ICM, CABG with gradual decline in activity over the past 6 months but the symptoms really started to limit his activities over one year ago. His renal, hepatic and lung function are at baseline and within normal age-‐appropriate limits. He has lost over 40lbs in the last two years and has a prealbumin of 13 and is cachectic in appearance. His wife (his primary support) has her own medical issues and his children live in a different state. His hemodynamics show an RA of 8, PA pressures of 40/20, a PCWP of 15, PA sat of 60% and a CI of 1.7. He has no interventional options nor does he have an ischemic burden. His physician has had to wean down his afterload reduction (including beta blocker) to lower doses over the past 6 months due to intolerance due to hypotension.

10:45 AM Case 2: 21 y/o AA F diagnosed at referring hospital with peripartum CM when experiencing dyspnea and hypotension shortly after emergency C-‐section. Echo noted severe global LV hypokinesis, LVEF 27%, dilated LV with moderate to severe MR. Responded quickly to diuretics (repeat echo 5 days later without significant change). Discharged on beta blocker, ACE-‐I, and wearable cardiac defibrillator. Labs unrevealing. Undergoing medication optimization (current: carvedilol 25mg bid, lisinopril 40 mg hs, eplerenone 12.5 mg qd, depot medroxyprogesterone acetate injections q3 months) with plan for repeat echo, and CPET. Self-‐ removed wearable defibrillator d/t contact dermatitis. Stable NHYA II.

11:00 AM Case 3: 40 y/o multiparous woman presents with cardiogenic shock and requires ecmo support. Etiology is unreversible (i.e not acute myocarditis). She is transitioned to a Thoratec HM II LVAD. She is evaluated for OHT and found to be a suitable candidate. Her PRAs are 99% with MFI’s >4000-‐7000 including A2.

11:15 AM Case 4: 74 yo M, NICM dx 2003. Hx: CRTD, PAF, VT, CKD, GIB/partial gastrectomy 1997, anemia (chronic iron infusions). LVEFs 20 -‐ 25%, LVEDD 7.3 -‐8.5 cm, severe MR. Stable many years, NYHA II through 2010 on full HF therapies. 2011 and again 2012 early DT LVAD evaluation considered for labile clinical state, yet RHC noted near normal filling pressures & borderline CI, peak VO2 18-‐19 ml/kg/min, so evaluations


deferred. 2012 SHFS survival 89% 1 yr, 56% 5 yrs. Late 2013 NYHA III, fall in VO2 to 12.1 ml/kg/min, RHC: RA 13, PA 54/23/37, PCW 27, CI 1.97 . Diuresed and screened for REVIVE-‐IT but marginally excluded for GFR. SHFS survival 64% 1 yr, 11% 5yrs. Without hospitalizations past 4 years but meticulously followed in HF clinic, home HF DMP. Some concerns over support systems, and pt willingness, delayed DT VAD evaluation until deterioration in April 2014 resulting in hospitalization, milrinone dependence, recurrence of AF with fall in CRT pacing. Completed LVAD eval and night prior to planned implant experienced GIB(EGD: erythematous and fraible mucosa in the gastric remnant s/p Billroth hemi-‐gastrectomy, no Mallory-‐Weiss tear). Discharged on warfarin, IV milrinone with tenuous clinical sate at home. After 4 weeks stable H&H underwent uncomplicated LVAD implant.

11:30 AM Case 5: 55y/o male with blood type O, BMI 32 presents with inotrope dependent end-‐stage CHF. The patient is evaluated and listed for OHT. His milrinone dose is 0.3mcg/kg/min. He is stable and well perfused on this dose. He is fully ambulatory and able to handle his CADD pump and is well-‐versed in handling his PICC line and inotropes. He has good family support.

11:45 AM Case 6: 66 y/o AA female with a NICM dx Feb 2012 w LVEF 25%. Hx morbid obesity, HTN, DM, COPD, OSA and hypoventilation syndrome (CPAP and 02 2L prn), anxiety/depression/binge eating, DJD and chronic back pain with limited mobility (walker, motorized wheelchair). On optimal HF therapies improved LVEF to normal Dec 2012. Remained NYHA IIIB. Jan 2014 on routine echo noted re-‐decline in LVEF to 35% without any change in clinical status or clear cause (no medication withdrawal, normal perfusion on nuclear stress). Subsequently underwent CRT-‐D for which HF team requested impedance technology. Over these 2 years her volume status fluctuated resulting in hospital admissions for both pulmonary edema, and for intravascular depletion, hypotension, AKF (precipitated by extreme variations in diet). Referred to nutritionist and psychiatrist.

12:00 PM Adjourn Learning objective: Using practice guidelines, research findings and clinical experience, make decisions about the management of difficult cases in heart failure. 10:30 AM – 12:00 PM Milano V-‐VI Heart Failure Clinical Trials: Future Challenges and Directions (Industry Session) Moderators: Barry H. Greenberg, San Diego, CA Bertram Pitt, Ann Arbor, MI 10:30 AM The Current State of Heart Failure Clinical Research in US Christopher M. O'Connor, Durham, NC 10:45 AM Clinical Trial Participation: Future Challenges for Academic Medical Centers Mihai Gheorghiade, Chicago, IL 11:15 AM Future Directions: The View from NHLBI Monica Shah, Washington, DC 11:30 AM Future Directions: The Industry View Robert J. Cody, New York, NY 11:45 AM Panel Discussion Faculty 12:00 PM Adjourn Learning objective: Describe the current state of HF clinical trials and how this might change in the future. 10:30 AM – 12:00 PM Milano VIII


JNC New Investigator Award: Basic Science Moderators: Douglas L. Mann, St. Louis, MO Douglas B. Sawyer, Nashville, TN 10:30 AM The Role of MLK3 in Inhibiting Cardiac Remodeling and Maintaining Left Ventricular

Function After Pressure Overload Robert A. U. Baumgartner1, Mark Aronovitz1, Roger Davis2, Robert M. Blanton1. 1Tufts Medical Center, Boston, MA; 2University of Massachusetts, Worcester, MA 10:53 AM The Matrix Metalloproteinase 13 -‐ Protease-‐Activated Receptor-‐1 Pathway

Contributes to Doxorubicin-‐Induced Cardiotoxicity Silvio Antoniak, Nigel Mackman. University of North Carolina at Chapel Hill, Chapel Hill, NC 11:15 AM An Innovative Needleless Liquid Jet Injection Delivery Method for Heart Failure Gene

Therapy: Preliminary Study Featuring AAV9 Demonstrates Greater Cardiac Specificity Versus Standard Approaches

Anthony S. Fargnoli1, Michael G. Katz1, Richard D. Williams1, Tracy L. Walling1, Kenneth B. Margulies2, Charles R. Bridges1. 1Carolinas Healthcare System, Charlotte, NC; 2University of Pennsylvania, Philadelphia, PA 11:38 AM M-‐Atrial Natriuretic Peptide: A Novel Designer Natriuretic Peptide with Sustained

Blood Pressure Lowering and Cyclic GMP Activating Actions in a Chronic Canine Model of Angiotensin II-‐Induced Hypertension

Giuseppe Puccia1,2, Sasantha J. Sangaralingham1, Gail Harty1, Alessandro Cataliotti1, Tomoko Ichiki1, Lorenzo Malatino2, John C. Burnett1. 1Mayo Clinic, Rochester, MN; 2University of Catania, Catania, Italy 12:00 PM Adjourn Learning objective: Discuss the results and implications of recent basic science research in heart failure. 10:30 AM – 12:00 PM Milano VII JNC New Investigator Award: Clinical/Integrative Moderators: Jay N. Cohn, Minneapolis, MN Kenneth B. Margulies, Philadelphia, PA 10:30 AM Low Pulsatility in the Early Post-‐Operative Setting Is Not Associated with

Gastrointestinal Bleeding in Patients Supported with Left Ventricular Assist Devices Christopher T. Sparrow, Michael E. Nassif, Adam Andruska, David S. Raymer, Eric Novak, Scott C. Silvestry, Gregory A. Ewald, Shane J. LaRue. Washington University in Saint Louis, St. Louis, MO 10:45 AM Muscle Wasting in Patients with Heart Failure with Preserved Ejection Fraction and Its

Impact on Muscle Strength and Functional Capacity during Exercise Tarek Bekfani1, Pierpaolo Pellicori2, Nicole Ebner1, Miroslava Valentova1, Anja Sandek1, Wolfram Doehner1, John Cleland2, Stefan Anker1, Stephan von Haehling1. 1Charité University Hospital, Virchow-‐Klinikum, Berlin, Germany; 2University of Hull, Hull, UK 11:00 AM Vascular Markers, Emerging Biomarkers in Heart Failure with Preserved Ejection

Fraction Muhammad Hammadah1, Yuping Wu2, Stanley L. Hazen3, W. H. Wilson Tang3. 1Cleveland Clinic, Cleveland, OH; 2Cleveland State University, Cleveland, OH; 3Cleveland Clinic, Cleveland, OH 11:15 AM Linking Old and New Concepts: Iron and Inflammation in Pulmonary Hypertension Alok Sharma, Thenappan Thenappan, Maria Patarroyo, Kairav Vakil, Marc Pritzker. University of Minnesota, Minneapolis, MN 11:30 AM Inorganic Nitrate Supplementation Improves Exercise Capacity in Subjects with HF

with Preserved EF -‐ A Pilot Study


Payman Zamani1, Deepa Rawat2, Prithvi Shiva Kumar3, Sam Geraci2, Rushik Bhuva2, Prasad Konda4,4, Paschalis-‐Thomas Doulias5, Harry Ischiropoulos5, Julio A. Chirinos6. 1Hospital of the University of Pennsylvania, Philadelphia, PA; 2Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; 3Hospital of the University of Pennsylvania & Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; 4Hospital of the University of Pennsylvania, Philadelphia, PA; 5Children's Hospital of Philadelphia Research Institute, Philadelphia, PA; 6Hospital of the University of Pennsylvania & Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 11:45 AM Pulmonary Vascular Response to Exercise in Heart Failure with Reduced Ejection

Fraction and Pulmonary Hypertension Frederik H. Verbrugge1, Matthias Dupont1, Philippe B. Bertrand1, Petra Nijst1, Lars Grieten1, Joseph Dens1, David Verhaert1, Stefan Janssens2, W.H. Wilson Tang3, Wilfried Mullens1. 1Ziekenhuis Oost-‐Limburg, Genk, Belgium; 2University Hospital Gasthuisberg/KU Leuven, Leuven, Belgium; 3Cleveland Clinic, Cleveland, OH 12:00 PM Adjourn 10-‐minute presentation, 5-‐minute discussion Learning objective: Discuss results of recent research and their implications for the treatment of heart failure. 10:30 AM – 12:00 PM Milano III Nursing Research Award Moderators: Corrine Y. Jurgens, Stony Brook, NY Kismet D. Rasmusson, Salt Lake City, UT 10:30 AM Symptom Trajectories in Coronary Artery Bypass Graft Patients With or Without Pre-‐

operative Heart Failure Ming Fen Tsai1, Tsuey-‐Yuan Huang1, Hui-‐Chu Yu2, Debra K. Moser3. 1Chang Gung University of Science and Technology, Taoyuan, Taiwan; 2National Taiwan University Hospital, Taipei, Taiwan; 3University of Kentucky, Lexington, KY 10:48 AM Cost Effectiveness of an Integrated Self Care Intervention for Persons with Heart

Failure and Diabetes Carolyn M. Reilly1, Melinda Higgins1, Javed Butler2, Rebecca Gary1, Steven D. Culler3,

Sandra B. Dunbar1. 11:06 AM Can Medications Be Safely Withdrawn in Patients With Chemotherapy-‐induced Heart

Failure With Recovered Heart Function? Anecita P. Fadol1, Jose Banchs2, Saamir Hassan2, Jean-‐Bernard Durand2, Valerie D. Shelton3, Bryan Fellman4, Edward T.H. Yeh2. 1MD Anderson Cancer Center, Houston, TX; 2MD Anderson Cancer Center, Houston, TX; 3MD Anderson Cancer Center, Houston, TX; 4MD Anderson Cancer Center, Houston, TX 11:24 AM The Influence of Social Support and Social Problem-‐Solving on Depressive

Symptomatology and Self-‐care Behaviors in Individuals with Heart Failure: A Structural Equation Modeling Study

Lucinda J. Graven1, Joan S. Grant2, David E. Vance2, Erica R. Pryor2, Laurie Grubbs1, Sally Karioth1. 1Florida State University, Tallahassee, FL; 2University of Alabama at Birmingham, Birmingham, AL 11:42 AM Palliative Care Services During Terminal Hospitalization: Stage D Heart Failure Patients Lisa A. Kitko, Judith E. Hupcey, Maureen Palese. The Pennsylvania State University, University Park, PA 12:00 PM Adjourn Learning objective: Discuss results of recent nursing research and their implications for the care of patients with HF. 12:15 PM – 1:15 PM Milano VII


How to Run an Effective Clinical Research Program Eugene S. Chung, Cincinnati, OH Linda H. Martin, Cincinnati, OH Mary N. Walsh, Indianapolis, IN Learning objective: Identify the components of an effective clinical research program and strategies for establishing and maintaining it. 12:15 PM – 1:15 PM Milano VIII How to Approach Difficult Conversations with Heart Failure Patients: Hoping for the Best, Planning for the Worst Ellin F. Gafford, Columbus, OH Ann S. Laramee, Burlington, VT Learning objective: Demonstrate effective communication skills and strategies in difficult patient conversations. 12:15 PM – 1:15 PM Milano I-‐II How to Develop a Shared Care Program for LVAD Patients Carol C. Ballew, Charlottesville, VA Michael S. Kiernan, Boston, MA Chetan B. Patel, Durham, NC Learning objective: Outline the components and advantages of a shared care program for LVAD patients. 12:15 PM – 1:15 PM Milano V How to Transition Patients into the Community Zubin J. Eapen, Durham, NC Hilary Law, Seattle, WA Sheryl L. Chow, Los Angeles, CA Learning objective: Describe key strategies for effectively transitioning HF patients into the community. 12:15 PM – 1:15 PM Milano III Rapid Fire Abstracts II Moderators: Joseph A. Hill, Dallas, TX Robb D. Kociol, Boston, MA End of Life/ Shared Decision-‐Making 12:15 PM Shared Decision-‐Making about End-‐of-‐Life Care for Heart Failure Patients with an

Implantable Cardioverter Defibrillator: A National Cohort Study Anna Strömberg1, Ingela Thylén1, Debra Moser2. 1Linköping University, Linköping, Sweden; 2University of Kentucky, Lexington, KY 12:20 PM End of Life Resource Utilization in Heart Failure Patients with Preserved and Reduced

Ejection Fraction Shannon M. Dunlay, Margaret M. Redfield, Susan A. Weston, Ruoxiang Jiang, Veronique L. Roger. Mayo Clinic Rochester, Rochester, MN 12:25 PM Patient-‐, Caregiver-‐, and Relationship-‐Level Characteristics Influence Heart Failure Self-‐

Care Maintenance Behaviors in Patient-‐Caregiver Dyads


Julie T. Bidwell1, Christopher S. Lee1, Karen S. Lyons1, Shirin O. Hiatt1, Rosaria Alvaro2, Ercole Vellone2, Barbara Riegel3. 1Oregon Health & Science University, Portland, OR; 2University of Rome Tor Vergata, Rome, Italy; 3University of Pennsylvania, Philadelphia, PA 12:30 PM Preliminary Evaluation of the Heart Failure Screening Tool (Heart-‐FaST): Assessing for

Patient Barriers to Engagement in Heart Failure Self-‐Care Jan Cameron, Tina Habota, Chantal F. Ski, Skye N. McLennan, Peter G. Rendell, David R. Thompson. Australian Catholic University, East Melbourne, Australia 12:35 PM Reducing Heart Failure Admissions Through Heart Success Transitional Care Model Deborah J. Fenner1, Sanjeev K. Gulati1, Karen Cloninger2, Meghan E. Emig1. 1Carolinas Medical Center, Charlotte, NC; 2Carolinas Medical Center-‐Lincoln, Lincolnton, NC 12:40 PM Learning from Heart Failure Patients to Improve Patient Centered Care Kismet Rasmusson, Stephanie Croasdell, Sean Meegan, Jen Nixon, A. G. Kfoury, Donald Lappe, Colleen Roberts, Deborah Budge. Intermountain Heart Institute, Salt Lake City, UT Diuretics/ Cardiorenal 12:45 PM Differential Cardiac versus Renal Response to Acute Volume Overload in Human

Preclinical Systolic Dysfunction and Renal Dysfunction with the Combination of PDEV Inhibition and BNP Administration

Isabel Torres Courchoud1, Paul M. McKie2, Sherry L. Benike1, John A. Schirger1, Margaret M. Redfield1, John C. Burnett Jr1, Horng H. Chen1. 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN 12:50 PM A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart

Failure: Insights from DOSE-‐AHF, CARRESS-‐HF, and ROSE-‐AHF Justin L. Grodin1, Susanna R. Stevens2, Lisa de las Fuentes3, Michael Kiernan4, Edo Y. Birati5, Divya Gupta6, Bradley A. Bart7, Michael Felker2, Horng H. Chen8, Javed Butler6, Victor G. Dávila-‐Román9, Kenneth B. Margulies5, Adrian Hernandez2, Kevin Anstrom2, W. H. Wilson Tang1. 1Cleveland Clinic, Cleveland, OH; 2Duke, Durham, NC; 3Washington University, St. Louis, MO; 4Tufts, Boston, MA; 5University of Pennsylvania, Philadelphia, PA; 6Emory, Atlanta, GA; 7Hennepin County Medical Center, Minneapolis, MN; 8Mayo Clinic, Rochester, MN; 9Washington University, St. Louis, MO 12:55 PM Differential Hemodynamic Effects of Exercise and Acute Volume Expansion in HFpEF Mads J. Andersen1, Thomas P. Olson1, Vojtech Melenovsky2, Garvan C. Kane1, Barry A. Borlaug1. 1Mayo Clinic, Rochester, MN; 2Institute for Clinical and Experimental Medicine, Prague, Czech Republic 1:00 PM Transient and Persistent Worsening Renal Function during Acute Heart Failure

Hospitalization: Insights from the ADHERE Registry Linked to Medicare Claims Arun Krishnamoorthy1,2, Melissa A. Greiner2, Puza P. Sharma3, Laura G. Qualls2, Adam D. DeVore1,2, Katherine Waltman Johnson3, Gregg C. Fonarow4, Lesley H. Curtis2, Adrian F. Hernandez1,2. 1Duke University School of Medicine, Durham, NC; 2Duke Clinical Research Institute, Durham, NC; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ; 4Ahmanson-‐UCLA Cardiomyopathy Center, Los Angeles, CA 1:05 PM Rapid Shallow Breathing Worsens Prior to Heart Failure Decompensation Alessandro Capucci1, Giulio Molon2, Michael R. Gold3, Yi Zhang4, Robert Sweeney4,

Viktoria Averina4, John P. Boehmer5. 1Università Politecnica delle Marche, Ancona, Italy; 2Sacro Cuore Hospital, Negrar, Italy; 3Medical University of South Carolina, Charleston, SC; 4Boston Scientific, St Paul, MN; 5Penn State

1:10 PM Distal Tubular Compensation as an Important Mechanistic Site of Diuretic Resistance in Heart Failure

Olga Laur1, Veena S. Rao1, Susan J. Cheng1, Alexander J. Kula1, Lavanya Bellumkonda1, Wilson W. H. Tang2, Chirag R. Parikh1, Jeffrey M. Testani1. 1Yale School of Medicine, New Haven, CT; 2Cleveland Clinic, Cleveland, OH 1:15 PM Adjourn Learning objective: Discuss recent research in end-‐of-‐life and shared decision-‐making and cardiorenal issues in HF. Abstracts/posters of interest: End of life: 145, 146, 150, 289, 300; Cardiorenal: 110, 125, 139, 176, 236


12:30 PM – 2:30 PM Neapolitan I Hands-‐on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices Chair: Joseph Rogers, Durham, NC Learning objective: Identify durable VADs, demonstrate their use, and describe effective patient selection, management,

and troubleshooting. Abstracts/posters of interest: 68, 69, 70, 75, 77, 79, 80, 81, 82, 83, 84, 86, 133, 141, 209, 212, 214, 216, 217, 218, 219, 220, 222, 224, 225, 226, 227, 280, 280, 284, 301, 312 1:20 PM – 3:00 PM Augustus I 1:20 PM Announcement of Awards David DeNofrio, Boston, MA Jeffery Molkentin, Cincinnati, OH Robin Trupp, Durham, NC Hyde Park Session Moderators: Paul J. Hauptman, St. Louis, MO Douglas D. Schocken, Durham, NC 1:30 PM Late Breaking Clinical Trials: Results of the Multicenter Meaningful use and

Maintenance of certification—Bringing Underutilized Life Long Systems-‐improvements to Heart failure Intervention Study (MMM-‐BULLSHIS)

Amrut V. Ambardekar, Aurora, CO 1:48 PM Use Evidence-‐based Medicine: Stop Treating Acute Heart Failure! John R. Teerlink, San Francisco, CA 2:06 PM How to Stop Poisoning and Love the (Redistribution) Syndrome Mark Dunlap, Cleveland, OH 2:24 PM New Study from New York Shows an Innovative Proprietary Intervention by the

Gambino Family Arvind Bhimaraj, Houston, TX 2:42 PM Marriage and the LVAD: ‘Til Death Do Us Part? Ali Javaheri, Philadelphia, PA 3:00 PM Adjourn Learning objective: Discuss new insights and perspectives on heart failure research, education, policy, and clinical practice. 1:30 PM – 3:00 PM Milano III Challenges and Controversies in Heart Failure Pharmacology Moderators: Sheryl L. Chow, Los Angeles, CA Mona Fiuzat, Durham, NC 1:30 PM The Anticoagulation Conundrum: Which Drug and When Shunichi Homma, New York, NY 1:45 PM Management of Mineralocorticoids: Optimal Dosing and Avoidance of Complications Gregg C. Fonarow, Los Angeles, CA 2:00 PM MRA in Patients with HFPEF: Mechanisms of Action and Implications for Future

Therapy Bertram Pitt, Ann Arbor, MI


2:15 PM Polypharmacy and Medication Complexity in Heart Failure Robert Lee Page II, Denver, CO 2:30 PM RAAS Inhibition in Chronic Kidney Disease Inder A. Anand, Minneapolis, MN 2:45 PM Panel Discussion Faculty 3:00 PM Adjourn Learning objective: Describe common challenges and dilemma in drug therapy for HF and recommendations for resolving them. Abstracts/posters of interest: 101, 110, 116, 169, 264, 274, 308 1:30 PM – 3:00 PM Milano VII International Session Moderators: Gerasimos Filippatos, Athens, Greece Thomas Force, Nashville, TN 1:30 PM Chronic Heart Failure Analysis and Registry in the Tohoku District of Japan-‐-‐The CHART

Studies Hiroaki Shimokawa, Sendai, Japan 1:45 PM Addressing Iron Deficiency in Heart Failure-‐-‐Update 2014 Stefan D. Anker, Berlin, Germany 2:00 PM LVAD Thrombosis-‐-‐A Piece of the Puzzle JoAnn Lindenfeld, Denver, CO 2:15 PM Acute Heart Failure-‐-‐Update 2014 Gerasimos Filippatos, Athens, Greece 2:30 PM Fibrotic Remodeling in the Ischemic Heart: Mechanisms to Address? Thomas Force, Nashville, TN 2:45 PM Panel Discussion Faculty 3:00 PM Adjourn Learning objective: Discuss significant issues in heart failure in the US, Europe, and Japan. 1:30 PM – 3:00 PM Milano VIII Reverse Remodeling and Myocardial Recovery Moderators: Stavros G. Drakos, Salt Lake City, UT Douglas L. Mann, St. Louis, MO 1:30 PM Basic Overview of Remodeling and Myocardial Recovery Kenneth B. Margulies, Philadelphia, PA 1:50 PM Mechanisms of Reverse Remodeling Richard Ha, Stanford, CA 2:10 PM How to Diagnose and Predict Sustained Myocardial Recovery Scott D. Solomon, Boston, MA 2:30 PM Mechanical Unloading of the Failing Human Heart: Atrophy or Recovery? Stavros G. Drakos, Salt Lake City, UT 2:50 PM Panel Discussion Faculty 3:00 PM Adjourn Learning objective: Describe the role of remodeling in the progression of HF and the mechanisms of reverse remodeling.


3:00 PM – 5:00 PM Neapolitan I Hands-‐on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices Chair: Joseph Rogers, Durham, NC Learning objective: Identify durable VADs, demonstrate their use, and describe effective patient selection, management,

and troubleshooting. Abstracts/posters of interest: 68, 69, 70, 75, 77, 79, 80, 81, 82, 83, 84, 86, 133, 141, 209, 212, 214, 216, 217, 218, 219, 220, 222, 224, 225, 226, 227, 280, 280, 284, 301, 312 3:30 PM – 5:00 PM Milano VIII cGMP Activating Pathways in Heart Failure: Clinical and Basic Insights Moderators: Robert Blanton, Boston, MA Marc J. Semigran, Boston, MA 3:30 PM Basic Evidence for PDE5 Inhibition in Heart Failure Rakesh Kukreja, Richmond, VA 3:45 PM Myocardial Natriuretic Peptide Signaling in Heart Failure: Basic Insights Issei Komuro, Tokyo, Japan 4:00 PM Nitric Oxide Donors in Heart Failure, Clinical Insights Clyde W. Yancy, Chicago, IL 4:15 PM Clinical Evidence for PDE5 Inhibitors in Heart Failure Marc J. Semigran, Boston, MA 4:30 PM Novel Natriuretic Peptides and Neprilysin Inhibitors in Heart Failure: Clinical Insights John C. Burnett Jr., Rochester, MN 4:45 PM Downstream Targets of cGMP-‐dependent Protein Kinase I in Heart Failure Eiki Takimoto, Baltimore, MD 5:00 PM Adjourn Learning objective: Describe the role of cGMP activating pathways in HF and their potential role as therapeutic targets. 3:30 PM – 5:00 PM Milano I Debates Moderators: John R. Teerlink, San Francisco, CA James E. Udelson, Boston, MA 3:30 PM Pro: ICD Generators at ERI Should Be Replaced Even Though the LVEF Has Normalized Richard Fogel, Indianapolis, IN 3:45 PM Con: ICD Generators at ERI Should Be Replaced Even Though the LVEF Has Normalized Jagmeet Singh, Boston, MA 3:45 PM Discussion 4:15 PM Pro: Legal Recreational Marijuana Use is Not a Contraindication to Cardiac

Transplantation Larry A. Allen, Denver, CO 4:30 PM Con: Legal Recreational Marijuana Use is Not a Contraindication to Cardiac

Transplantation Jon A. Kobashigawa, Los Angeles, CA 4:45 PM Discussion


5:00 PM Adjourn Learning objective: Discuss the pros and cons of replacing ICD generators at ERI with normalized LVEF and legal mariljuana use as a contraindication to cardiac transplantation. 3:30 PM – 5:00 PM Milano VII Heart Failure and Cardiac Rehabilitation: What Clinicians Need to Know Moderators: Sara C. Paul, Hickory, NC Ann S. Laramee, Burlington, VT 3:30 PM What is the Evidence for Cardiac Rehabilitation in HFrEF and HFpEF? Gordon R. Reeves, Philadelphia, PA 3:50 PM What Can Cardiac Rehab Do for My Patients with HF? Patricia Davidson, Baltimore, MD 4:10 PM Which Patients Do I Refer? Nancy Houston-‐Miller, Palo Alto, CA 4:30 PM Regulatory and Legislative Update Linda Baas, Cincinnati, OH 4:50 PM Panel Discussion Faculty 5:00 PM Adjourn Learning objective: Describe the role of cardiac rehabilitation in HF management in the context of regulatory changes. 3:30 PM – 5:00 PM Milano V How to Select Patients for Advanced Therapies (ISHLT Joint Session) Moderators: Donna M. Mancini, New York, NY Mandeep R. Mehra, Boston, MA 3:30 PM Are We There Yet? How to Determine When You Have Reached the Limits of Medical

Therapy Sean P. Pinney, New York, NY 3:45 PM My Patient is on Inotropes But Has No Device—To CRT or Not JoAnn Lindenfeld, Denver, CO 4:00 PM Inotropes Aren't All Bad, Are They? Lee R. Goldberg, Philadelphia, PA 4:15 PM LVAD vs. BiVAD vs. TAH: Who, What, When, Where and Why? Jeffrey J. Teuteberg, Pittsburgh, PA 4:30 PM But She's a Healthy 70 Year Old! Savitra E. Fedson, Chicago, IL 4:45 PM Panel Discussion Faculty 5:00 PM Adjourn Learning objective: Outline the selection process for advanced therapies in heart failure.


WEDNESDAY, SEPTEMBER 167 7:00 AM – 8:15 AM Milano V Clinical Fundamentals III: The Basics of Mechanical Circulatory Support Moderators: Michael A. Acker, Philadelphia, PA Joseph G. Rogers, Durham, NC 7:00 AM Axial and Centrifugal Continuous Flow LVADs: Differentiating Flow and Design

Characteristics Francis D. Pagani, Ann Arbor, MI 7:15 AM LVAD Implantation: Surgical Considerations Soon J. Park, Cleveland, OH 7:30 AM Patient Selection: Assessment of End Organ Function and the Right Ventricle Salpy V. Pamboukian, Birmingham, AL 7:45 AM Short and Long-‐Term Complications of Continuous Flow LVADs Jennifer L. Peura, Charleston, SC 8:00 AM BTT and DT Outcomes: Insights from INTERMACS Jason N. Katz, Chapel Hill, NC 8:00 AM Discharge Teaching and Outpatient Assessments Linda J. Ordway, Boston, MA 8:15 AM Adjourn Learning objective: Describe the role of mechanical circulatory support in the management of HF; identify critical issues and care strategies. Abstracts/posters of interest: 68, 69, 70, 75, 77, 79, 80, 81, 82, 83, 84, 86, 133, 141, 209, 212, 214, 216, 217, 218, 219, 220, 222, 224, 225, 226, 227, 280, 280, 284, 301, 312 8:15 AM – 8:30 AM Neapolitan I HFSA Business Meeting Michele Blair, Chevy Chase, MD 8:30 AM – 10:00 AM Milano VIII Emerging Roles for Advanced Imaging in Unexplained Cardiomyopathy Moderator: Leslie T. Cooper, Rochester, MN 8:30 AM Clinical Clues that Suggest a Specific Etiology for Idiopathic Dilated Cardiomyopathy Dennis M. McNamara, Pittsburgh, PA 8:50 AM The Role of EP Mapping to Guide Endomyocardial Biopsy in Unexplained

Cardiomyopathy Surja Kapa, Rochester, MN 9:10 AM Newer MRI Techniques to Distinguish Myocardial Inflammation from Scar Godfred Holmvang, Boston, MA 9:30 AM The Role of Positron Emission Tomography Imaging in Unexplained Cardiomyopathy Edward J. Miller, Boston, MA 9:50 AM Panel Discussion Faculty 10:00 AM Adjourn Learning objective: Identify advanced imaging options and their role in diagnosing unexplained cardiomyopathies. Abstracts/posters of interest: 194, 195, 271, 301


8:30 AM – 10:00 AM Milano V HFpEF: What We Do and Don't Know Moderators: Barry A. Borlaug, Rochester, MN James C. Fang, Salt Lake City, UT 8:30 AM How Do We Define It? Scott D. Solomon, Boston, MA 8:50 AM What Causes It? Barry A. Borlaug, Rochester, MN 9:10 AM How Do We Treat It? Margaret M. Redfield, Rochester, MN 9:30 AM HFpEF—Disease or Syndrome? Mathew S. Maurer, New York, NY 9:50 AM Panel Discussion Faculty 10:00 AM Adjourn Learning objective: Describe the current understanding of HFpEF and use recommended treatment strategies. 8:30 AM – 10:00 AM Milano VII Improving Patient Satisfaction Scores: Strategies to Make Them Love You Moderators: J. Thomas Heywood, La Jolla, CA Robin J. Trupp, Durham, NC 8:30 AM Introduction Robin J. Trupp, Durham, NC 8:45 AM Quietness Campaigns Allen Cadavero, Durham, NC 9:00 AM Bedside Rounds Mitchell T. Saltzberg, Newark, DE 9:15 AM The Compassionate Professional: The Heart of Patient Centered Care Joan Forte Scott, Stanford, CA 9:30 AM What Success Looks Like Invited 9:45 AM Panel Discussion Faculty 10:00 AM Adjourn Learning objective: Outline strategies for improving patient satisfaction scores. 8:30 AM – 10:00 AM Milano III New Challenges in Cardiac Transplantation Moderators: Howard J. Eisen, Philadelphia, PA Leslie W. Miller, Tampa, FL 8:30 AM Heart Allocation Policy in the US: Are There Opportunities for Improvement? Jon A. Kobashigawa, Los Angeles, CA 8:50 AM Heart Transplantation in Amyloidosis: Update on Patient Selection and Outcomes Mark Jay Zucker, Newark, NJ 9:10 AM Proliferation Signal Inhibitors: When and How Should We Be Initiating Therapy?


Sudhir S. Kushwaha, Rochester, MN 9:30 AM New Strategies in Organ Preservation: An Update on PROCEED II Abbas Ardehali, Los Angeles, CA 9:50 AM Panel Discussion Faculty 10:00 AM Adjourn Learning objective: Describe current heart allocation policy in the US, strategies for patient selection in transplantation with amyloidosis, and other issues in cardiac transplantation. Abstracts/posters of interest: 078, 132, 211, 218, 222, 267, 276 10:30 AM – 12:00 PM Milano III Not All Readmissions Should Be Avoided: When to Readmit Patients with Heart Failure Moderators: Karol Harshaw-‐Ellis, Durham, NC Julie A. Shinn, Stanford, CA 10:30 AM Perspectives from the Emergency Department Phillip D. Levy, Detroit, MI 10:45 AM Key Clinical Triggers for the Admission of Patients with “Worsening” Heart Failure Marie Galvao, New York, NY 11:00 AM Arrhythmic Indications for Heart Failure Admissions Linda K. Ottoboni, Stanford, CA 11:15 AM The Patient on Mechanical Circulatory Support Linda J. Ordway, Boston, MA 11:30 AM Case Studies Faculty 12:00 PM Adjourn Learning objective: Identify patients with HF who should be readmitted. Abstracts/posters of interest: 85, 113, 117, 119, 123, 124, 126, 130, 131, 135, 143, 145, 146, 175, 178, 217, 222, 243, 264, 265, 276, 277, 280, 283, 285, 287, 296, 297, 300, 309, 313, 314 10:30 AM – 12:00 PM Milano V Right Ventricular Failure After LVAD Implantation Moderators: Keith D. Aaronson, Ann Arbor, MI Duc Thinh Pham, Boston, MA 10:30 AM Current Epidemiology of Right Heart Failure After LVAD Implantation Robert Kormos, Pittsburgh, PA 10:45 AM Prediction of Right Heart Failure: Clinical Models Sean P. Pinney, New York, NY 11:00 AM Pathophysiology of RVF in LVAD Recipients Edwin C. McGee Jr., Chicago, IL 11:15 AM Echocardiography as a Patient Selection Tool for LVAD: Where Do We Stand? Andreas P. Kalogeropoulos, Atlanta, GA 11:30 AM Case Studies Keith D. Aaronson, Ann Arbor, MI 12:00 PM Adjourn Learning objective: Describe the epidemiology and pathophysiology of right HF after LVAD implantation; discuss means to identify patient risk. 10:30 AM – 12:00 PM


Milano VII 50 Shades of Technology in the Management of Heart Failure Moderators: Robert Lee Page II, Denver, CO Robin C. Trupp, Durham, NC 10:30 AM Medication Adherence: Emerging Use of Technology Jo Ellen Rodgers, Chapel Hill, NC 10:50 AM Can Heart Faillure Device Monitoring Be Done in the Home? Lee R. Goldberg, Philadelphia, PA 11:10 AM I Can See You: The Use of TeleHealth Technology in HF Management Linda L. Wick, Duluth, MN 11:30 AM Is There an App for That?—The Use of Smartphones in Heart Failure Management Zubin J. Eapen, Durham, NC 12:00 PM Adjourn Learning objective: Describe technologies that can improve clinicians’ and patients’ abilities to manage HF.

!SUNDAY,!SEPTEMBER!14! ·...

Documents

Transcript of !SUNDAY,!SEPTEMBER!14! ·...